Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.30 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491623 | 0.88 | HDAC8 (0.38) | STING1NR1H2HDAC8CNR2CNR1 | |
| SCHEMBL2492655 | 0.85 | DYRK1A (0.39) | KDM4EALDH1A1POLBTDP1LMNA | |
| SCHEMBL13938651 | 0.85 | STING1 (0.34) | STING1NR1H2HDAC8CNR2CNR1 | |
| SCHEMBL13008095 | 0.84 | HDAC8 (0.35) | STING1NR1H2KDM4EHDAC8CNR2 | |
| SCHEMBL530612 | 0.82 | LTA4H (0.40) | STING1KDM4EHDAC8CNR2ALDH1A1 | |
| SCHEMBL1742929 | 0.81 | BCHE (0.48) | CNR2BCHETDP1SUCNR1 | |
| SCHEMBL1744457 | 0.81 | BCHE (0.48) | CNR2BCHETDP1SUCNR1 | |
| SCHEMBL530477 | 0.81 | PDE3B (0.30) | STING1 | |
| SCHEMBL14986214 | 0.80 | LTA4H (0.40) | KDM4EHDAC8CNR2ALDH1A1CNR1 | |
| SCHEMBL18900144 | 0.79 | LTA4H (0.42) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2170890-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | STING1 655/4885NR1H2 4000/4885KDM4E 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.